On March 16, 2016, Lu, Xianping; Yu, Jindi; Yang, Qianjiao; Li, Zhibin; Pan, Desi; Shan, Song; Zhu, Jiangfei; Wang, Xianghui; Liu, Xiangheng; Ning, Zhiqiang published a patent.Safety of N-(3-Aminophenyl)acrylamide The title of the patent was Preparation of pyrimidine derivatives and their application as the inhibitor of JAK. And the patent contained the following:
The invention is related to the preparation of pyrimidine derivatives I and their application as the inhibitor of JAK. The invention compounds I, wherein X is halogen; R1 is H, cyano, halogen, etc.; R2 is H or halo; R3 is C1-6 alkyl or substituted alkyl; n is integer of 1-7; p is integer of 1-3; A is C6-10 aryl or C5-10 heteroaryl; and their pharmaceutically acceptable salts are claimed. Compound I was prepared by multi-step procedure (procedure given). The pyrimidine derivatives I or pharmaceutically acceptable salts have JAK kinase inhibitory activity, especially have selectivity and high inhibitory activity on JAK3 kinase, and can be used for preparing JAK3 kinase inhibitors as well as medicines for prevention or treatment of diseases related to JAK3 kinase activity abnormity, so as to prevent or treat diseases related to JAK3 kinase activity abnormity. From assay, it was determined that I exhibited the IC50 value of 0.65-1.22 uM against JAK1. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Safety of N-(3-Aminophenyl)acrylamide
The Article related to preparation pyrimidine derivative application inhibitor jak, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Safety of N-(3-Aminophenyl)acrylamide
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics